drugset / Trial / NCT07227779
B-PaLMZ for TB Meningitis
Phase 2
Not yet recruiting
240 enrolled
University of Minnesota
Infectious Diseases Institute · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This two-stage study will compare consented research participants with tuberculous meningitis receiving BPaLMZ to controls receiving SOC of rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E), known as RHZE.
Timeline
- Start
- 2026-07-20
- Primary completion
- 2030-08-31
- Completion
- 2030-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bedaquiline | Small molecule | — | — |
| Subject | Linezolid | Other / unclassified | — | — |
| Subject | Moxifloxacin | Small molecule | — | — |
| Subject | Pretomanid | Small molecule | — | — |
| Subject | Pyrazinamide | Small molecule | — | — |